Neurologic complications of arrhythmia treatment

Handbook of Clinical Neurology

Volumn 119, Issue , 2014, Pages 129-150

  Leary, Megan C ^a   Veluz, Jeffrey S ^b   Caplan, Louis R ^c  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b ST LUKE S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cardioembolic; Diagnosis; Etiology; Ischemic; Management; Stroke

Indexed keywords

ART; ARTICLE; CARDIOEMBOLIC; CEREBROVASCULAR ACCIDENT; DIAGNOSIS; ETIOLOGY; HEART ARRHYTHMIA; HUMAN; ISCHEMIC; MANAGEMENT; NEUROLOGIC DISEASE;

CARDIOEMBOLIC; DIAGNOSIS; ETIOLOGY; ISCHEMIC; MANAGEMENT; STROKE;

ARRHYTHMIAS, CARDIAC; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 84890868917     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-7020-4086-3.00010-2     Document Type: Chapter

References (252)

1. Abdon N.J., Johnsson B.M. High risk of embolization in episodic sick sinus syndrome 1979, 11-14. PACESYMP, Montreal.
2. Abi-Mansour P., Carberry P.A., McCowan R.J., Henthorn R.W., Dunn G.H., Perry K.T. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am Heart J 1998, 136:632-642.
3. ACTIVE Investigators, Connolly S.J., Pogue J., Hart R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Eng J Med 2009, 360:2066-2078.
4. Adams H.P. Neurologic complications of cardiovascular procedures. Iatrogenic Neurology 1998, 51-61. Butterworth-Heinemann, Boston. J. Biller (Ed.).
5. Agarwal S.K., Heiss G., Rautaharju P.M., et al. Premature ventricular complexes and the risk of incident stroke: the Atherosclerosis Risk In Communities (ARIC) Study. Stroke 2010, 41:588-593.
6. Agius M.A., Zhu S., Fairclough R.H. Antirapsyn antibodies in chronic procainamide-associated myopathy (CPAM). Ann N Y Acad Sci 1998, 841:527-529.
7. Ahmad S. Procainamide and peripheral neuropathy. South Med J 1982, 74:509-510.
8. Ahmad S. Diltiazem myopathy. Am Heart J 1993, 126:1494-1495.
9. Aho K., Haapa K. Facial atrophy during sotalol treatment. J Neurol Neurosurg Psychiatry 1982, 45:179.
10. Allen M.J., Nichols D.J., Oliver S.D. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. Br J Clin Pharmacol 2000, 50:247-253.
11. Alvarez M., Merino J.L. Spanish registry on catheterablation: 1st official report of the working group on electrophysiology and arrhythmias of the Spanish Society of Cardiology (Year 2001). Rev Esp Cardiol 2002, 55:1273-1285.
12. Anderson N.E., Lynch N.M., O'Brien K.P. Disabling neurological complications of amiodarone. Aust N Z J Med 1985, 15:300-304.
13. Arnold A.Z., Mick M.J., Mazurek R.P., et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992, 19:851-855.
14. Aronow W.S., Ahn C., Mercando A.D., et al. Correlation of paroxysmal supraventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1476 old-old patients. Aging 1996, 8:32-34.
15. Atkinson J.L., Sundt T.M., Kazmier F.J., et al. Heparin-induced thrombocytopenia and thrombosis in ischemic stroke. Mayo Clin Proc 1988, 63:353-361.
16. Atluru V.L., Epstein L.G., Gootman N. Childhood stroke and supraventricular tachycardia. Pediatr Neurol 1985, 1:54-56.
17. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrialfibrillation. Analysis of pooled data from five, randomized controlled trials. Arch Intern Med 1994, 154:1449.
18. Babikian V.L., Kase C.S., Pessin M.S., et al. Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke 1989, 20:1500-1503.
19. Bai R., Patel D., Di Biase L., et al. Phrenic nerve injury after catheter ablation: should we worry about this complication?. J Cardiovasc Electrophysiol 2006, 17:944-948.
20. Banach M., Kazmierski J., Kowman M., et al. Atrial fibrillation as a nonpsychiatric predictor of delirium after cardiac surgery: a pilot study. Med Sci Monit 2008, 14:CR286-CR291.
21. Barbut D., Caplan L.R. Brain complications of cardiac surgery. Curr Probl Cardiol 1997, 22:455-476.
22. Barnett S.D., Ad N. Surgical ablation as treatment for the elimination of atrial fibrillation: a meta-analysis. J Thorac Cardiovasc Surg 2006, 131:1029-1035.
23. Bathen J., Span S., Rokseth R. Embolism in sinoatrial disorder. Acta Med Scand 1978, 203:7-11.
24. Bell J.A., Hodgson H.J. Coma after cardiac arrest. Brain 1974, 97:361-372.
25. Berchtold-Kanz E., Schwarz G., Hust M., et al. Increased incidence of side effects after encainide: a newly developed antiarrhythmic drug. Clin Cardiol 1984, 7:493-497.
26. Berwaerts J., Webster J. Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages. Q J Med 2000, 93:513-521.
27. Bhushan M., Asirvatham S.J. The conundrum of ventricular arrhythmia and cardiomyopathy: which abnormality came first?. Curr Heart Fail Rep 2009, 6:7-13.
28. Bikadoroff S. Mental changes associated with tocainide, a new antiarrhythmic. Can J Psychiatry 1987, 32:219-221.
29. Billett H.H., Scorziello B.A., Giannattasio E.R., et al. Low molecular weight heparin bridging for atrial fibrillation: is VTE thromboprophylaxis the major benefit?. J Thromb Thrombolysis 2010, 30:479-485.
30. Birk S., Petersen K.A., Kruuse C., et al. The effect of circulating adenosine on cerebral haemodynamics and headache generation in healthy subjects. Cephalalgia 2005, 25:369-377.
31. Blessing W., Walsh J.C. Myotonia precipitated by propranolol therapy. Lancet 1977, 1:73-74.
32. Block P.C., Burstein S., Casale P.N., et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study. J Am Coll Cardiol Intv 2009, 2:594-600.
33. Bogousslavsky J., Van Melle G., Regli F. The Lausanne Stroke Registry: analysis of 1000 consecutive patients with first strokes. Stroke 1988, 19:1083-1092.
34. Bogousslavsky J., Cachin C., Regli F., et al. Cardiac sources of embolism and cerebral infarction: clinical consequences and vascular concomitants. The Lausanne Stroke Registry. Neurology 1991, 41:855-859.
35. Bonatz E., Seabol K.E. Acute carpal tunnel syndrome in a patient taking coumadin: case report. J Trauma 1993, 35:143-144.
36. Borger van der Burg A.E., de Groot N.M., van Erven L., et al. Long-term follow-up after radiofrequency catheter ablation of ventricular tachycardia: a successful approach?. J Cardiovasc Electrophysiol 2002, 13:424-426.
37. Borruat F.X., Regli F. Pseudotumor cerebri as a complication of amiodarone therapy. Am J Ophthalmol 1993, 116:776-777.
38. Boston Collaborative Drug Surveillance Program [no authors listed] Drug-induced convulsions. Report from Boston Collaborative Drug Surveillance Program. Lancet 1972, 2:677-679.
39. Brantigan J.W., Owens M.L., Moody F.G. Femoral neuropathy complicating anticoagulant therapy. Am J Surg 1976, 132:108-109.
40. Briani C., Zara G., Negrin P. Disopyramide-induced neuropathy. Neurology 2002, 58:663.
41. Brown S.G.A., Waterer G.W. Migraine precipitated by adenosine. Med J Aust 1995, 162:389-391.
42. Brown C., Bachmann G., Ling F.W. Differential diagnosis of seizure associated with topical lidocaine in a patient with vestibulodynia. J Low Genit Tract Dis 2009, 13:51.
43. Butterfield W.C., Neviaser R.J., Roberts M.P. Femoral neuropathy and anticoagulants. Ann Surg 1972, 176:58-61.
44. Campbell R.W. Mexiletine. N Engl J Med 1987, 316:29-34.
45. Campbell N.P., Kelly J.G., Shanks R.G., et al. Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet 1973, 2:404-407.
46. Candell J., Valle V., Soler M., et al. Acute intoxication with verapamil. Chest 1979, 75:200-201.
47. Cannon B.C., Kertesz N.J., Friedman R.A., et al. Use of tissue plasminogen activator in a stroke after radiofrequency ablation of a left-sided accessory pathway. J Cardiovasc Electrophysiol 2001, 12:723-725.
48. Caplan L.R. Cardiac arrest and other hypoxic-ischemic insults. Clinical Neurocardiology 1999, 1-34. Marcel Dekker, New York. L.R. Caplan, J.W. Hurst, M.I. Chimowitz (Eds.).
49. Caplan L.R. Encephalopathies and neurological effects of drugs used in cardiac patients. Clinical Neurocardiology 1999, 186-225. Marcel Dekker, New York. L.R. Caplan, J.W. Hurst, M.I. Chimowitz (Eds.).
50. Caronna J.J., Finkelstein S. Neurological syndromes after cardiac arrest. Stroke 1978, 9:517-520.
51. Cerebral Embolism Task Force Cardiogenic brain embolism: the second report of the Cerebral Embolism Task Force. Arch Neurol 1989, 46:727-743.
52. Charness M.E., Morady F., Scheinman M.M. Frequent neurologic toxicity associated with amiodarone therapy. Neurology 1984, 34:669-671.
53. Chua T.P., Farrell T., Lipkin D.P. Myoclonus associated with propafenone. BMJ 1994, 308:113.
54. Clark C.W.F., El-Mahdi E.O. Fatal tocainide over-dosage. BMJ 1984, 288:760.
55. Closson R.G. Visual hallucinations as the earliest symptom of digoxin intoxication. Arch Neurol 1983, 40:386.
56. Cohen I.S., Jick H., Cohen S.I. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis 1977, 20:151-163.
57. Collaborative Group for the Study of Polyneuropathy Antiarrhythmic drugs and polyneuropathy. J Neurol Neurosurg Psychiatry 1994, 57:340.
58. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
59. Coulter D.M., Edwards I.R., Savage R.L. Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme. N Z Med J 1990, 103:98-100.
60. Cox J.L., Canavan T.E., Schuessler R.B., et al. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991, 101:406-426.
61. Dabbert O., Freeman D.G., Weis A.J. Spinal meningeal hematoma, warfarin therapy, and chiropractic adjustment. JAMA 1970, 214:2058.
62. Das G., Ferris J.C. Generalized convulsions in a patient receiving ultrashort-acting beta-blocker infusion. Drug Intell Clin Pharm 1988, 22:484-485.
63. Dawkins K.D., Gibson J. Peripheral neuropathy with disopyramide. Lancet 1978, 1:329.
64. De Pedis G., Hedner K., Johansson B.W., et al. Cardiac arrhythmia in geriatric patients with organic dementia. Compr Gerontol A 1987, 1:115-117.
65. Di Biase L., Burkhardt J.D., Mohanty P., et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010, 121:2550-2556.
66. Dick R.S., Barold S.S. Diltiazem-induced parkinsonism. Am J Med 1989, 87:95-96.
67. DiMarco J.P., Garan H., Ruskin J.N. Complications in patients undergoing cardiac electrophysiologic procedures. Ann Intern Med 1982, 97:490-493.
68. Dorf E., Kuntz A.F., Kelsey J., et al. Lidocaine-induced altered mental status and seizure after hematoma block. J Emerg Med 2006, 31:251-253.
69. Dotti M.T., Federico A. Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. Mov Disord 1995, 10:233-234.
70. Drachman D.A., Skom J.H. Procainamide - a hazard in myasthenia gravis. Arch Neurol 1965, 13:316-320.
71. Meyler's Side Effects of Drugs 1975, Vol. VIII. Excerpta Medica, Amsterdam. M.N. Dukes (Ed.).
72. Duraković Z., Plavsić F., Smalcelj A., et al. Blue color vision as a sign of digitalis poisoning. Lijec Vjesn 1992, 114:132-134.
73. Eisenman D.P., McKegney F.P. Delirium at therapeutic serum concentrations of digoxin and quinidine. Psychosomatics 1994, 35:91-93.
74. Emara M.K., Saadah A.M. The carpal tunnel syndrome in hypertensive patients treated with beta-blockers. Postgrad Med J 1988, 64:191-192.
75. Ettorre E., Cicerchia M., De Benedetto G., et al. A possible role of atrial fibrillation as a risk factor for dementia. Arch Gerontol Geriatr 2009, 49(Suppl 1):71-76.
76. Ewy G.A. Optimal technique for electrical cardioversion of atrial fibrillation. Circulation 1992, 86:1645-1647.
77. Fairfax A.J., Lambert C.D., Leathan M.A. Systemic embolization in chronic sinoatrial disorder. N Engl J Med 1976, 295:190-192.
78. Fernando Roth R., Itabashi H., Louie J., et al. Amiodarone toxicity: myopathy and neuropathy. Am Heart J 1990, 119:1223-1225.
79. Fesler M.J., Creer M.H., Richart J.M., et al. Heparin-induced thrombocytopenia and cerebral venous sinus thrombosis: case report and literature review. Neurocrit Care 2011, 15:161-165.
80. Fisher C.M. Visual disturbances associated with quinidine and quinine. Neurology 1981, 31:1569-1571.
81. Fisher M., Kase C.S., Stelle B., et al. Ischemic stroke after cardiac pacemaker implantation in sick sinus syndrome. Stroke 1988, 19:712-715.
82. Fisher A.A., Davis M., Jeffery I. Acute delirium induced by metoprolol. Cardiovasc Drugs Ther 2002, 16:161-165.
83. Fogoros R.N., Anderson K.P., Winkle R.A., et al. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation 1983, 68:88-94.
84. Forrence E., Covinsky J.O., Mullen C. A seizure induced by concurrent lidocaine-tocainide therapy - is it just a case of additive toxicity?. Drug Intell Clin Pharm 1986, 20:56-59.
85. Fuster V., Halperin J.L. Left ventricular thrombi and cerebral embolism. N Engl J Med 1989, 320:392-394.
86. Galasso P.J., Stanton M.S., Vogel H. Propafenone-induced peripheral neuropathy. Mayo Clin Proc 1995, 70:469-472.
87. Gammie J.S., Didolkar P., Krowsoski L.S., et al. Intermediate-term outcomes of surgical atrial fibrillation correction with the CryoMaze procedure. Ann Thorac Surg 2009, 87:1452-1458.
88. Garcia-Albea E., Jimenez-Jimenez F.J., Ayuso-Peralta L., et al. Parkinsonism unmasked by verapamil. Clin Neuropharmacol 1993, 16:263-265.
89. Gaynor S.L., Schuessler R.B., Bailey M.S., et al. Surgical treatment of atrial fibrillation: predictors of late recurrence. J Thorac Cardiovasc Surg 2005, 129:104-111.
90. Gentzkow G.D., Sullivan J.Y. Extracardiac adverse effects of flecainide. Am J Cardiol 1984, 53:101B-105B.
91. Gillinov A.M. Advances in surgical treatment of atrial fibrillation. Stroke 2007, 38:618-623.
92. Gödecke-Koch T., Schlimme J., Rada D., et al. Charles Bonnet syndrome in an elderly patient with bilateral vision loss, hyperthyroidism and relative digitalis overdose. Nervenarzt 2002, 73:471-474.
93. Godley P.J., Morton T.A., Karboski J.A., et al. Procainamide-induced myasthenic crisis. Ther Drug Monit 1990, 12:411-414.
94. Goli-Bijanki R., Nair C.K., Nair N., et al. Previously unreported adverse reaction to encainide. Chest 1989, 96:688-689.
95. Graham D.F., Stewart-Wynne E.G. Diltiazem-induced acute parkinsonism. Aust N Z J Med 1994, 24:70.
96. Greenspon A.J., Hart R.G., Dawson D., et al. MOST Study Investigators. Predictors of stroke in patients paced for sick sinus syndrome. J Am Coll Cardiol 2004, 43:1617-1622.
97. Greif S., Roth F., Harnoncourt K. The treatment of angina pectoris with a fixed combination of a beta-receptor and a long-acting nitrate. Praxis 1977, 66:1554-1559.
98. Grogan W.A., Narkun D.M. Pseudotumor cerebri with amiodarone. J Neurol Neurosurg Psychiatry 1987, 50:651.
99. Guieu R., Devaux C., Henry H., et al. Adenosine and migraine. Can J Neurol Sci 1998, 25:55-58.
100. Harik S.I., Raichle M.E., Reis D.J. Spontaneously remitting spinal epidural hematoma in a patient on anticoagulants. N Engl J Med 1971, 284:1355-1357.
101. Hecaen H., Ajuriaguerra J. Balint's syndrome and its minor forms. Brain 1954, 77:373-400.
102. Herishanu Y., Rosenberg P. Beta-blockers and myasthenia gravis (letter). Ann Intern Med 1975, 83:834-835.
103. Hindle J.V., Ibrahim A., Ramaraj R. Ataxia caused by amiodarone in older people. Age Ageing 2008, 37:347-348.
104. Hohnloser S.H., Crijns H.J., van Eickels M., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009, 360:668-678.
105. Holmes D.R., Reddy V.Y., Turi Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet 2009, 374:534-542.
106. Holt P. Visual hallucinations. N Z Med J 1988, 101:29.
107. Horn H.R., Hadidian Z., Johnson J.L., et al. Safety evaluation of tocainide in the American Emergency Use Program. Am Heart J 1980, 100:1037-1040.
108. Hylek E.M., Singer D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994, 120:897-902.
109. Ilia R., Goldfarb B., Gueron M. Skin thickening and sensory loss of the feet during diltiazem therapy. Int J Cardiol 1992, 35:115.
110. Isbister G.K. Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium. Emerg Med J 2002, 19:355-357.
111. Ishida S., Sugino M., Hosokawa T., et al. Amiodarone-induced liver cirrhosis and parkinsonism: a case report. Clin Neuropathol 2010, 29:84-88.
112. Jacobs J.M., Costa-Jussà F.R. The pathology of amiodarone neurotoxicity. II. Peripheral neuropathy in man. Brain 1985, 108:753-769.
113. Jones R.J., Brace S.R., Vander Tuin E.L. Probable propafenone-induced transient global amnesia. Ann Pharmacother 1995, 29:586-590.
114. Kaplan B.M. Sick sinus syndrome. Arch Intern Med 1978, 138:28.
115. Kase C.S., Robinson R.K., Stein R.W., et al. Anticoagulant-related intracerebral hemorrhage. Neurology 1985, 35:943-948.
116. Kashyap A.S., Anand K.P., Kashyap S. Severe ataxia caused by amiodarone. Am J Cardiol 2006, 97:1550-1551.
117. Kennerdy A., Thomas P., Sheridan D.J. Generalized seizures as the presentation of flecainide toxicity. Eur Heart J 1989, 10:950-954.
118. King R.B., Bechtold D.L. Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy. Ann Emerg Med 1985, 14:362-364.
119. Kittner S.J., Sharkness C.M., Sloan M., et al. Infarcts with a cardiac source of embolism in the NINDS Stroke Data Bank: neurologic examination. Neurology 1992, 42:299-302.
120. Klein A.L., Grimm R.A., Black I.W., et al. Cardioversion guided by transesophageal echocardiography. The ACUTE Pilot Study. A randomized, controlled trial. Ann Intern Med 1997, 126:200-209. for the ACUTE Investigators.
121. Kornfeld P., Horowitz S.H., Genkins G., et al. Myasthenia gravis unmasked by antiarrhythmic agents. Mt Sinai J Med 1976, 43:10-14.
122. Krauser D.G., Segal A.Z., Kligfield P. Severe ataxia caused by amiodarone. Am J Cardiol 2005, 96:1463-1464.
123. Kumana C.R., Mahon W.A. Bizarre perceptual disorder of extremities in patients taking verapamil. Lancet 1981, 1:1324-1325.
124. Lazo-Langner A., Rodger M.A., Wells P.S. Lessons from ximelagatran: issues for future studies evaluating new oral direct thrombin inhibitors for venous thromboembolism prophylaxis in orthopedic surgery. Clin Appl Thromb Hemost 2009, 15:316-326.
125. Leary M.C., Caplan L.R. Cerebrovascular disease and neurologic manifestations of heart disease. Hurst's The Heart: Manual of Cardiology 2009, 640-647. McGraw-Hill, New York, ch. 35. 12th edn. R.A. O'Rourke, R.A. Walsh, V. Fuster (Eds.).
126. Lecky B.R., Weir D., Chong E. Exacerbation of myasthenia by propafenone. J Neurol Neurosurg Psychiatry 1991, 54:377.
127. Lederle F.A., Cundy K.V., Farinha P., et al. Spinal epidural hematoma associated with warfarin therapy. Am J Med 1996, 100:237-238.
128. Lee T.C. Van Gogh's vision. Digitalis intoxication?. JAMA 1981, 245:727-729.
129. Lévy S. Internal defibrillation: where we have been and where we should be going?. J Interv Card Electrophysiol 2005, 13(Suppl 1):61-66.
130. Levy D., Carrona J.J., Singer B.H., et al. Predicting outcome from hypoxicischemic coma. JAMA 1985, 253:1420-1426.
131. Levy S., Lauribe P., Dolla E., et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992, 86:1415-1420.
132. Levy S., Ricard P., Lau C.P., et al. Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol 1997, 29:750-755.
133. Li Y., Tian L., Huang Y., et al. Pharmacokinetic and pharmacodynamic properties of a single intravenous dose of ibutilide fumarate: a phase I, randomized, open-label, increasing-dose study in healthy Chinese men. Clin Ther 2007, 29:1957-1966.
134. Liebeschuetz S., Baddeley H., Thomas D.J.B. Haematomyelia following warfarin therapy. Br J Clin Pharmacol 1994, 48:105-106.
135. Linazasoro G., Martí-Massó J.F., Urtasun M., et al. Paroxysmal dystonia induced by exercise secondary to flecainide. Neurologia 1991, 6:344.
136. Longstreth W.T., Inui T.S., Cobb L.A., et al. Neurologic recovery after out-of-hospital cardiac arrest. Ann Intern Med 1983, 38:588-592.
137. Longstreth W.T., Diehr P., Inui T.S. Prediction of awakening after out-of-hospital cardiac arrest. N Engl J Med 1983, 308:1378-1382.
138. Love J.N., Handler J.A. Toxic psychosis: an unusual presentation of propranolol intoxication. Am J Emerg Med 1995, 13:536-537.
139. Lown B., Amarasingham R., Neuman J. New method for terminating cardiac arrhythmias: use of synchronized capacitor discharge. JAMA 1962, 182:548-555.
140. Mahitchi E., Balagué F., Waldburger M. What is your diagnosis? Myopathy due to hypothyroidism aggravated by amiodarone. Praxis 2009, 98:999-1000.
141. Malcolm N., Callegari P., Goldberg J., et al. Massive diltiazem overdosage: clinical and pharmacokinetic observations. Drug Intell Clin Pharm 1986, 20:888.
142. Maloney J.D., Nissen R.G., McColgan J.M. Open clinical studies at a referral center: chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmia agents. Am Heart J 1980, 100:1023-1030.
143. Manning W.J., Silverman D.I., Gordon S.P., et al. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993, 328:750-755.
144. Manolis A.S., Tordjman T., Mack K.D., et al. Atypical pulmonary and neurologic complications of amiodarone in the same patient. Report of a case and review of the literature. Arch Intern Med 1987, 147:1805-1809.
145. Marke J., Steinberg M.D., Rabiner C.J. "Doom anxiety" and delirium in lidocaine toxicity. Am J Psychiatry 1987, 144:159-163.
146. Maryniak A., Bielawska A., Walczak F., et al. Long-term cognitive outcome in teenage. Resuscitation 2008, 77:46-50.
147. Mattioli A.V., Tarabini Castellani E., Mattioli G. Stroke in paced patients with sick sinus syndrome: influence of left atrial function and size. Cardiology 1999, 91:150-155.
148. McClelland J.H., Duke D., Reddy R. Preliminary results of a limited thoracotomy: new approach to treat atrial fibrillation. J Cardiovasc Electrophysiol 2007, 18:1289-1295.
149. Mehall J.R., Kohut R.M., Schneeberger E.W., et al. Intraoperative epicardial electrophysiologic mapping and isolation of autonomic ganglionic plexi. Ann Thorac Surg 2007, 83:538-541.
150. Meschia J.F., Biller J. Complications of cardiovascular drugs. Iatrogenic Neurology 1998, 379-396. Butterworth-Heinemann, Boston. J. Biller (Ed.).
151. Michel R.H., Alevizatos A.C. Femoral neuropathy: a complication of anticoagulation. Md Med J 1975, 24:57.
152. Miller L.G., Jankovic J. Persistent dystonia possibly induced by flecainide. Mov Disord 1992, 7:62-63.
153. Miller C.D., Oleshansky M.A., Gibson K.F., et al. Procainamide-induced myasthenia-like weakness and dysphagia. Ther Drug Monit 1993, 15:251-254.
154. Mindel J.S. Amiodarone and optic neuropathy. Am Heart J 2008, 156:411-413.
155. Missault L., Jordaens L., Gheeraert P., et al. Embolic stroke after unanticoagulated cardioversion despite prior exclusion of atrial thrombi by transoesophageal echocardiography. Eur Heart J 1994, 15:1279-1280.
156. Morell J., Sullivan B., Khalabuda M., et al. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban. J Clin Pharmacol 2010, 50:986-1000.
157. Moroni F., Mannaioni P.F., Dolara A., et al. Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning. Clin Toxicol 1980, 17:395-400.
158. Moyer R.R. Verapamil, an anti-anginal agent. Minn Med 1972, 55:1043-1045.
159. Murphy M.A., Nye D.H. Thoracic intramedullary haematoma as a complication of warfarin: case report and literature review. Aust N Z J Surg 1991, 61:789-792.
160. Nabavi D.G., Allroggen A., Reinecke H., et al. Absence of circulating microemboli in patients with atrial fibrillation undergoing electric cardioversion. Cerebrovasc Dis 2001, 11:95-99.
161. Niakan E., Bertorini T.E., Acchiardo S.R., et al. Procainamide-induced myasthenia-like weakness in a patient with peripheral neuropathy. Arch Neurol 1981, 38:378-379.
162. Nygaard T.W., Sellers T.D., Cook T.S., et al. Adverse reactions to antiarrhythmic drugs during therapy for ventricular arrhythmias. JAMA 1986, 256:55-57.
163. O'Brien S.M., Shahian D.M., Filardo G., et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2. Isolated valve surgery. Ann Thorac Surg 2009, 88:S23-S42.
164. Odeh M., Seligmann H., Oliven A. Propafenone-induced ataxia: report of three cases. Am J Med Sci 2000, 320:151-153.
165. Oh S.J., Elmore R.S., Sarala P.K., et al. Procainamide-induced myasthenia-like syndrome. Muscle Nerve 1986, 9:670-672.
166. Ozdemir M., Türkoglu S., Kaya M.G., et al. Prospective randomized trial of transthoracic versus low-energy internal cardioversion in persistent atrial fibrillation: long term follow-up. Int Heart J 2006, 47:753-762.
167. Palace J., Shah R., Clough C. Flecainide induced peripheral neuropathy. BMJ 1992, 305:810.
168. Palakurthy P.R., Iyer V., Meckler R.J. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern Med 1987, 147:881-884.
169. Parnass S.M., Rothenberg D.M., Fischer R.L., et al. Spinal anesthesia and mini-dose heparin (letter). JAMA 1990, 263:1496.
170. Passal D.B., Crespin F.H. Verapamil poisoning in an infant. Pediatrics 1984, 73:543-545.
171. Pathirana K.D., Hidelaratchi M.D. Exacerbation of symptoms due to diltiazem in a patient with Lambert-Eaton myasthenic myopathic syndrome. Ceylon Med J 2004, 49:130-131.
172. Pellissier J.F., Pouget J., Cros D., et al. Peripheral neuropathy induced by amiodarone chlorhydrate. A clinicopathological study. J Neurol Sci 1984, 63:251-266.
173. Pelter M.A., Vollmer T.A., Blum R.L. Seizure-like reaction associated with subcutaneous lidocaine injection. Clin Pharm 1989, 8:767-768.
174. Perucca E., Pickles H., Richens A. Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects. Clin Pharmacol Ther 1981, 29:425-433.
175. Pickles H., Perucca E., Fish A., et al. Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor. Clin Pharmacol Ther 1981, 30:303-310.
176. Pohl C., Harbrecht U., Greinacher A., et al. Neurologic complications in immune-mediated heparin-induced thrombocytopenia. Neurology 2000, 54:1240-1245.
177. Preobrazhenski D.V., Sidorenko B.A., Kiktev V.G., et al. Stroke and other thromboembolic complications of atrial fibrillation. Part VII. Prevention of cardioversion related thromboembolism. Kardiologiia 2005, 45:78-82.
178. Prystowsky E.N. Management of atrial fibrillation. Simplicity surrounded by controversy. Ann Intern Med 1997, 126:244-246.
179. Przybylski A., Sterliński M., Lewandowski M., et al. Risk of thromboembolic complications in patients with permanent atrial fibrillation undergoing cardioverter-defibrillator implantation. Kardiol Pol 2002, 57:306-312.
180. Puccio D., Novo G., Baiamonte V., et al. Atrial fibrillation and mild cognitive impairment: what correlation?. Minerva Cardioangiol 2009, 57:143-150.
181. Pullarkat V.A., Kalapura T., Pincus M., et al. Intraspinal hemorrhage complicating oral anticoagulant therapy. Arch Intern Med 2000, 160:237-240.
182. Purvin V., Kawasaki A., Borruat F.X. Optic neuropathy in patients using amiodarone. Arch Ophthalmol 2006, 124:696-701.
183. Radford D.J., Julian D.G. Sick sinus syndrome: experience of a cardiac pacemaker clinic. Br Med J 1974, 3:504-507.
184. Ramhamadany E., Mackenzie S., Ramsdale D.R. Dysarthria and visual hallucinations due to flecainide toxicity. Postgrad Med J 1986, 62:61-62.
185. Ravid S., Podrid P.J., Novrit B. Safety of long-term propafenone therapy for cardiac arrhythmia: experience with 774 patients. J Cardiovasc Electrophysiol 1987, 6:580-590.
186. Reithmann C., Hahnefeld A., Fiek M., et al. Invasive electrophysiology: complications, nightmares and their management. Herzschrittmacherther Elektrophysiol 2007, 18:204-215.
187. Roberts R. Metoprolol prevented myocardial infarction but increased risk of stroke and death after non-cardiac surgery. Evid Based Med 2008, 13:175.
188. Rosenqvist M., Brandt J., Schüller H. Atrial versus ventricular pacing in sinus node disease: a treatment comparison study. Am Heart J 1986, 111:292-297.
189. Rumbak M.J., Chokshi S.K., Abel N., et al. Left phrenic nerve paresis complicating catheter radiofrequency ablation for Wolff-Parkinson-White syndrome. Am Heart J 1996, 132:1281-1285.
190. Sacco R.L., Adams R., Albers G., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke - co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006, 37:577-617.
191. Saccomanno G., Fraticelli A., Marini M., et al. Permanent ventricular and dual chamber cardiac stimulation: role of pacing mode in relation to chronic atrial fibrillation risk and stroke development. Arch Gerontol Geriatr 1999, 29:61-74.
192. Sacher F., Monahan K.H., Thomas S.P., et al. Phrenic nerve injury after atrial fibrillation catheter ablation: characterization and outcome in a multicenter study. J Am Coll Cardiol 2006, 47:2498-2503.
193. Saeed M., Rahman A., Afzal A., et al. Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillation, previous left atrial thrombus and effective anticoagulation. Int J Cardiol 2006, 113:401-405.
194. Sahenk Z., Mendell J.R., Rossio J.L., et al. Polyradiculoneuropathy accompanying procainamide-induced lupus erythematosus: evidence for drug-induced enhanced sensitization to peripheral nerve myelin. Ann Neurol 1977, 1:378-384.
195. Samniah N., Schlaeffer F. Cerebral infarction associated with oral verapamil overdose. Clin Toxicol 1988, 26:365-369.
196. Sánchez-Quintana D., Ho S.Y., Climent V., et al. Anatomic evaluation of the left phrenic nerve relevant to epicardial and endocardial catheter ablation: implications for phrenic nerve injury. Heart Rhythm 2009, 6:764-768.
197. Satya-Murti S., Heiman T., Martinez L.B. Possible propranolol myotonin association. N Engl J Med 1977, 297:223-224.
198. Sauvé M.J., Doolittle N., Walker J.A., et al. Factors associated with cognitive recovery after cardiopulmonary resuscitation. Am J Crit Care 1996, 5:127-139.
199. Sayler D.J., DeJong D.J. Possible procainamide-induced myopathy. DICP 1991, 25:436.
200. Schmitt C., Alt E., Plewan A., et al. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol 1996, 28:994-999.
201. Schneider M.C., Caliezi C., Seeberger M.D. Antiplatelet therapy or low-dose heparin and neuraxial anesthaesia. Acta Anaesthesiol Scand 1997, 41:219-221.
202. Sgarbossa E.B., Pinski S.L., Maloney J.D., et al. Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome. Relevance of clinical characteristics and pacing modalities. Circulation 1993, 88:1045-1053.
203. Shah A.R., Passalacqua B.R. Case report: sustained-release verapamil overdose causing stroke: an unusual complication. Am J Med Sci 1992, 304:357-359.
204. Shahian D.M., O'Brien S.M., Filardo G., et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1. Coronary artery bypass grafting surgery. Ann Thorac Surg 2009, 88:S2-S22.
205. Shahian D.M., O'Brien S.M., Filardo G., et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 3. Valve plus coronary artery bypass grafting surgery. Ann Thorac Surg 2009, 88:S43-S62.
206. Sherman D.G. Stroke prevention in atrial fibrillation: pharmacological rate versus rhythm control. Stroke 2007, 38(2 Suppl):615-617.
207. Siddoway L.A., Roden D.M., Woosley R.L. Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. Am J Cardiol 1984, 54:9D-12D.
208. Silver J.R., Buxton P.H. Spinal stroke. Brain 1974, 97:539-550.
209. Silverman D.I., Manning W.J. Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation. Circulation 1998, 98(Suppl I):479-486.
210. Singh A., Singh P., Singh P. Oral use of low dosage schedule Isoptin verapamil in cardiac arrhythmias. Indian J Med Sci 1976, 30:7-11.
211. Sosa E., Scanavacca M., d'Avila A., et al. A new technique to perform epicardial mapping in the electrophysiology laboratory. J Cardiovasc Electrophysiol 1996, 7:531-536.
212. Soyka L.F. Safety of encainide for the treatment of ventricular arrhythmias. Am J Cardiol 1986, 58:96C-103C.
213. Sperry K., Wohlenberg N., Standefer J.C. Fatal intoxication by tocainide. J Forensic Sci 1987, 32:1440-1446.
214. Sproule D.M., Kaufmann P., Engelstad K., et al. Wolff-Parkinson-White syndrome in patients with MELAS. Arch Neurol 2007, 64:1625-1627.
215. Sra J.S., Maglio C., Dhala A., et al. Feasibility of atrial fibrillation detection and use of a preceding synchronization interval as a criterion for shock delivery in humans with atrial fibrillation. J Am Coll Cardiol 1996, 28:1532-1538.
216. Sternlo J.E., Hybbinette C.H. Spinal subdural bleeding after attempted epidural and subsequent spinal anaesthesia in a patient on thromboprophylaxis with low molecular weight heparin. Acta Anaesthesiol Scand 1995, 39:557-559.
217. Stone J.M., Bhakta R.D., Lutgen J. Dual chamber sequential pacing management of sinus node dysfunction: advantages over single chamber pacing. Am Heart J 1982, 104:1319-1326.
218. Streib E.W. Successful treatment with tocainide of recessive generalized congenital myotonia. Ann Neurol 1986, 19:501-504.
219. Summers W.K., Allen R.E., Pitts F.N. Does physostigmine reverse quinidine delirium?. West J Med 1981, 135:411-414.
220. Susens G.P. Femoral neuropathy. Arch Intern Med 1974, 133:171.
221. Tanel R.E., Walsh E.P., Triedman J.K., et al. Five-year experience with radiofrequency catheter ablation: implications for management of arrhythmias in pediatric and young adult patients. J Pediatr 1997, 131:878-887.
222. Teichman S.L., Ferrick A., Kim S.G., et al. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. J Am Coll Cardiol 1987, 10:633-641.
223. Teräväinen H. Beta-blockers in isoproterenol-enhanced essential tremor. Acta Neurol Scand 1984, 69:125-127.
224. Tordjman T., Podrid P.J., Raeder E., et al. Safety and efficacy of encainide for malignant ventricular arrhythmias. Am J Cardiol 1986, 58:87C-95C.
225. Tracy C.M., Akhtar M., DiMarco J.P., et al. American College of Cardiology/American Heart Association clinical competence statement on invasive electrophysiology studies, catheter ablation, and cardioversion: a report of the American College of Cardiology/American Heart Association/American College of Physicians - American Society of Internal Medicine Task Force on Clinical Competence. Circulation 2000, 102:2309-2320.
226. Tuka V., Ricarova B., Janota T., et al. Surprisingly delayed escalation of severe verapamil poisoning. Eur J Emerg Med 2009, 16:100-102.
227. Turkewitz L.J., Sahgal V., Spiro A. Propranolol-induced myotonia. Mt Sinai J Med 1984, 51:207.
228. Ueno S., Hara Y. Lambert-Eaton myasthenic syndrome without anti-calcium channel antibody: adverse effect of calcium antagonist diltiazem. J Neurol Neurosurg Psychiatry 1992, 55:409-410.
229. Vadlamudi L., Wijdicks E.F.M. Multifocal myoclonus due to verapamil overdose. Neurology 2002, 58:984-985.
230. van der Vleuten P.A., van den Brink E., Schoonderwoerd B.A., et al. Delirium attributed to the use of metoprolol. Ned Tijdschr Geneeskd 2005, 149:2183-2186.
231. van Sambeek M.R., Segeren C.M., van Dijk L.C., et al. Endovascular repair of an extracranial internal carotid artery aneurysm complicated by heparin-induced thrombo cytopenia and thrombosis. J Endovasc Ther 2000, 7:353-358.
232. Venkayya R.V., Poole R.M., Pentz W.H. Respiratory failure from procainamide-induced myopathy. Ann Intern Med 1993, 119:345-346.
233. Verbrugge L.B., van Wezel H.B. Pathophysiology of verapamil overdose: new insights in the role of insulin. J Cardiothorac Vasc Anesth 2007, 21:406-409.
234. Visentin G.P., Ford S.E., Scott J.P., et al. Thrombotic complications from HIT can include cerebral infarction, which often occurs 5-15 days after the start of heparin. J Clin Invest 1994, 93:81-88.
235. Volans A.P. The risks of minor head injury in the warfarinised patient. J Accid Emerg Med 1998, 15:159-161.
236. Volpe B.T., Soave R. Formal visual hallucinations as digitalis toxicity. Ann Intern Med 1979, 91:868-869.
237. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
238. Wei L., Li X.Q., Liu Z.H. Myopathy induced by amiodarone treatment: a case report. Zhonghua Xin Xue Guan Bing Za Zhi 2007, 35:93.
239. Weinberg D.M., Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 1989, 63:745-746.
240. Werner E.G., Olanow C.W. Parkinsonism and amiodarone therapy. Ann Neurol 1989, 25:630-632.
241. White W.B., Johnson M.F., Anders R.J., et al. Safety of controlled-onset extended-release veapamil in middle-aged and older patients with hypertension and coronary artery disease. Am Heart J 2001, 142:1010-1015.
242. Wijdicks E. Neurologic complications of drug overdose, poisoning, and terrorism. Neurologic Complications of Critical Illness 2009, 316-333. Oxford University Press, New York. 3rd edn. E. Wijdicks (Ed.).
243. Williams L.S., Biller J. Neurologic complications of anticoagulant and antiplatelet drugs. Iatrogenic Neurology 1998, 379-396. Butterworth-Heinemann, Boston. J. Biller (Ed.).
244. Wolf P. Creativity and chronic disease, Vincent van Gogh (1853-1890). West J Med 2001, 175:348.
245. Wolf P.A., Abbot R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987, 147:1561-1564.
246. Wolman R.L., Nussmeier N.A., Aggarwal A., et al. Cerebral injury after cardiac surgery: identification of a group at extraordinary risk. Stroke 1999, 30:514-522.
247. Worthington J.M., Gattellari M., Leung D.Y. "Where there's smoke. . ." Are premature ventricular complexes a new risk factor for stroke?. Stroke 2010, 41:572-573.
248. Wozakowska-Kapłon B., Opolski G., Kosior D., et al. Cognitive disorders in elderly patients with permanent atrial fibrillation. Kardiol Pol 2009, 67:487-493.
249. Yapa R.S., Green G.J. Embolic stroke following cardioversion of atrial fibrillation to sinus rhythm with oral amiodarone therapy. Postgrad Med J 1990, 66:410.
250. Younge B.R. Amiodarone and ischemic optic neuropathy. J Neuroophthalmol 2007, 27:85-86.
251. Zanetti L.A. Sotalol: a new class III antiarrhythmic agent. Clin Pharm 1993, 12:883-891.
252. Zapson D.S., Riviello J.J., Bagwell S. Supraventricular tachycardia leading to stroke in childhood. J Child Neurol 1995, 10:239-241.